---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-031241"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2026-05-06T23:59:59+00:00"
generated_at: "2026-05-14T22:34:26.991197+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vanda Q1 net loss widens to $0.82/share; raises FY2026 revenue guidance on NEREUS launch

## Summary
- Fanapt net product sales $29.6M (+26% YoY); total prescriptions +32%, new-to-brand +76%.
- NEREUS (tradipitant) launched via direct-to-consumer platform; first new motion sickness drug in 40+ years.
- FY2026 revenue guidance raised to $240-290M from $230-260M, including $10-30M from NEREUS.
- Net loss $48.6M ($0.82 diluted EPS) vs loss $29.5M ($0.50) in Q1 2025.
- BYSANTI (milsaperidone) received FDA approval Feb 20 for bipolar I and schizophrenia.

## SEC filing metadata
- accession: 0001628280-26-031241
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2026-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/vnda-20260506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-031241
- JSON: https://secwatch.observer/filing/0001628280-26-031241.json
- Plain text: https://secwatch.observer/filing/0001628280-26-031241.txt

## Source-grounded claims
- claim_id: 687a284791838b833f438af70664f18e0f5ec6a2
  claim: Vanda Pharmaceuticals Inc. reported the first quarter ended March 31, 2026 results: revenue $51.7 million, net income net loss of $48.6 million (diluted loss per share of $0.82), EPS (diluted loss per share of $0.82). Guidance raised.
  evidence_excerpt: pipeline progress and our raised 2026 revenue guidance, position the company for continued growth and value creation.” Financial Highlights • Total net product sales reached $51.7 million in Q1 2026, a 3% increase compared to $50.0 million in Q1 2025. • Fanapt ® net product sales were $29.6 million, up 26% year-over-year. • HETLIOZ ® net product sales were $15.9
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828026031241/0001628280-26-031241-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.